真实世界证据解决方案市场－全球产业规模、份额、趋势、机会和预测，按组件、治疗领域、地区和竞争格局划分，2020-2030 年预测

2024年全球真实世界证据解决方案市场规模为29.8亿美元，预计2030年将以8.99%的复合年增长率成长至50亿美元。全球真实世界证据（RWE）解决方案市场涵盖了用于收集、分析真实世界资料并从中产生临床见解的综合技术和服务，旨在为各种医疗决策提供资讯。该市场的主要驱动因素包括：监管机构对药物研发和审批中RWE的认可度不断提高、对基于价值的医疗模式的需求日益增长，以及对高效上市后监测的需求不断扩大。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球真实世界证据解决方案市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按组成部分（理赔资料、临床设定资料、病患提供的资料、药局资料、其他组成部分）
  • 依治疗领域（肿瘤学、免疫学、神经病学、心血管疾病、其他治疗领域）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美真实世界证据解决方案市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲真实世界证据解决方案市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区真实世界证据解决方案市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲真实世界证据解决方案市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲真实世界证据解决方案市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球真实世界证据解决方案市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development (PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Real-World Evidence Solutions Market , valued at USD 2.98 Billion in 2024, is projected to experience a CAGR of 8.99% to reach USD 5.00 Billion by 2030. The Global Real-World Evidence (RWE) Solutions Market encompasses the comprehensive technology and services employed for collecting, analyzing, and generating clinical insights from real-world data to inform diverse healthcare decisions. This market is primarily driven by the increasing regulatory acceptance of RWE in drug development and approvals, the growing demand for value-based care models, and the expanding need for efficient post-market surveillance.

Key Market Drivers

The global Real-World Evidence Solutions Market is fundamentally influenced by increasing regulatory acceptance and the profound shift towards value-based healthcare models. Regulatory bodies globally are progressively integrating real-world evidence into drug development and post-market surveillance. This evolution supports accelerated therapy development by validating outcomes derived from routine clinical practice. According to GlobeNewswire, in August 2024, 82% of drug submissions to the FDA included Real-World Evidence, up from 73% in 2022, demonstrating growing reliance on these solutions for regulatory decision-making. This emphasis by regulators highlights the need for robust real-world data collection and analysis.

Key Market Challenges

The persistent issue of data interoperability and standardization across fragmented global healthcare systems directly impedes the growth of the Global Real-World Evidence Solutions Market. This challenge stems from the diverse formats, terminologies, and governance structures prevalent in real-world data generated across various clinical settings, electronic health record systems, and administrative databases worldwide. Consequently, the seamless aggregation and comprehensive analysis of this disparate data are significantly hindered, demanding extensive manual efforts and complex data harmonization processes. This operational complexity escalates the time and resources required to synthesize meaningful clinical insights, thereby diminishing the efficiency and scalability of real-world evidence initiatives.

Key Market Trends

The integration of artificial intelligence (AI) and machine learning (ML) in Real-World Evidence (RWE) analytics represents a transformative trend, enhancing the ability to derive deep insights from complex datasets. These advanced technologies facilitate more efficient data processing, pattern identification, and predictive modeling, which are crucial for accelerating drug development and optimizing treatment pathways. According to eClinical Solutions' 2024 Industry Outlook, 53% of respondents from clinical operations, data management, and biometrics functions believed AI and ML would have the greatest impact on efficiency and outcomes in 2024, signifying growing industry confidence in these tools. For example, IQVIA announced a collaboration with NVIDIA in January 2025, deploying over 50 AI agents trained on 1.2 billion health records to streamline workflows in life sciences, which demonstrates how AI is directly contributing to faster drug discovery timelines and improved decision-making within the RWE solutions market.

Key Market Players

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development (PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

Report Scope:

In this report, the Global Real-World Evidence Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Real-World Evidence Solutions Market , By Component:

• Claims Data
• Clinical Settings Data
• Patient-Powered Data
• Pharmacy Data
• Other Components

Real-World Evidence Solutions Market , By Therapeutic Area:

• Oncology
• Immunology
• Neurology
• Cardiovascular Disease
• Other Therapeutic Areas

Real-World Evidence Solutions Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Real-World Evidence Solutions Market .

Available Customizations:

Global Real-World Evidence Solutions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Real-World Evidence Solutions Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, Other Components)
  • 5.2.2. By Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease, Other Therapeutic Areas)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Real-World Evidence Solutions Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Real-World Evidence Solutions Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada Real-World Evidence Solutions Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico Real-World Evidence Solutions Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Real-World Evidence Solutions Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Real-World Evidence Solutions Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France Real-World Evidence Solutions Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Real-World Evidence Solutions Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Real-World Evidence Solutions Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Real-World Evidence Solutions Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Real-World Evidence Solutions Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Real-World Evidence Solutions Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Real-World Evidence Solutions Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan Real-World Evidence Solutions Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea Real-World Evidence Solutions Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Real-World Evidence Solutions Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Real-World Evidence Solutions Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Real-World Evidence Solutions Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE Real-World Evidence Solutions Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa Real-World Evidence Solutions Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Therapeutic Area

10. South America Real-World Evidence Solutions Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Real-World Evidence Solutions Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia Real-World Evidence Solutions Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina Real-World Evidence Solutions Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Real-World Evidence Solutions Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Clinigen Group PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Icon PLC
• 15.3. IBM Corporation
• 15.4. IQVIA Inc.
• 15.5. Oracle Corporation
• 15.6. Parexel International
• 15.7. PerkinElmer Inc.
• 15.8. Pharmaceutical Product Development (PPD Inc.)
• 15.9. SAS Institute Inc.
• 15.10. Syneos Health Inc.

16. Strategic Recommendations

17. About Us & Disclaimer